Michael Cecchini

List of Publications by Citations

Source: https://exaly.com/author-pdf/8858255/michael-cecchini-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers 131 5 h-index g-index

21 203 7.6 avg, IF L-index

#	Paper	IF	Citations
19	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016 , 16, 46	7 ^{4.8}	43
18	Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options in Oncology, 2020, 21, 70	5.4	37
17	Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical Cancer Research, 2019 , 25, 2049	·2 05 .ō	26
16	Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant 2015 , 3, 10		10
15	Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. <i>Lancet Oncology, The</i> , 2018 , 19, 23-24	21.7	5
14	A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. <i>Cancer</i> , 2021 , 127, 1417-1424	6.4	3
13	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 307-318	7.3	3
12	Introduction to the Yale Precision Medicine Tumor Board. Lancet Oncology, The, 2018, 19, 19-20	21.7	2
11	Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by -Mediated Resistance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1085-1089	7-3	1
10	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clinical and Translational Radiation Oncology, 2021, 27, 15-23	4.6	1
9	Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. <i>Oncologist</i> , 2021 , 26, 660-667	5.7	O
8	Clinical outcomes of first line FOLFIRINOX gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 2547-2556	2.8	O
7	Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System <i>Journal of Clinical Oncology</i> , 2020 , 38, 769-76	9 ^{2.2}	
6	Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study <i>Journal of Clinical Oncology</i> , 2020 , 38, 770-770	2.2	
5	Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. <i>Lancet Oncology, The</i> , 2021 , 22, 306-307	21.7	
4	Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients <i>Journal of Clinical Oncology</i> , 2021 , 39, 462-462	2.2	
3	Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?. <i>Abdominal Radiology</i> , 2021 , 46, 5609-5617	3	

- QIM22-192: Mismatch Repair Protein Immunohistochemistry: Quality of Mismatch Repair Deficiency Detection. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, QIM22-192³
- Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.. *JMIR Cancer*, **2022**, 8, e33859

3.2